Catabasis Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Astria Therapeutics

15/05/2021 03:35

* Catabasis Pharmaceuticals Inc  CATB.OQ  reported a quarterly
adjusted loss of 24 cents​​ per share for the quarter ended
in March. The mean expectation of three analysts for the quarter
was for a loss of 15 cents per share.
* Reported revenue was zero​;  analysts expected zero. 
* Catabasis Pharmaceuticals Inc's reported EPS for the quarter
was a loss of $7.60​.
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Catabasis Pharmaceuticals Inc shares had fallen by 39.8% this
quarter and lost 18.7% so far this year.
* The company reported a quarterly loss of $170.08 million.
* Wall Street's median 12-month price target for Catabasis
Pharmaceuticals Inc is $5.50 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
This summary was machine generated May 15 at 02:35 a.m. GMT.
​All figures in US dollars